Albireo Pharma, Inc.

📍 Boston, United States👥 196 employees💰 Last funded Jun 2018
Biotechnology Research🌐 albireopharma.com
Website LinkedIn
On March 2, 2023, Albireo was acquired by Ipsen, strengthening Ipsen’s rare disease portfolio with promising therapeutics for pediatric and adult rare liver diseases. Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com. 
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Albireo Pharma, Inc.?
Albireo Pharma, Inc. has 2 investors on record on gritt.io.
When did Albireo Pharma, Inc. last raise funding?
The most recent investment in Albireo Pharma, Inc. recorded on gritt.io was in June 2018.
What industry is Albireo Pharma, Inc. in?
Albireo Pharma, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Albireo Pharma, Inc. based?
Albireo Pharma, Inc. is headquartered in Boston, United States.